Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Suzanna Liu"'
Autor:
Christopher I. Bayly, Dan McKay, Tom Y.-H. Wu, Patrick Roy, Suzanna Liu, Michel Gallant, Austin Chen, Helene Juteau, Rejean Fortin, Daniel Dube, Renee Aspiotis, Patrick Lacombe
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 20:5822-5826
The discovery and SAR of a series of potent renin inhibitors possessing a novel biaryl scaffold are described herein. Molecular modeling revealed that the cyclopropylamide spacer present in 1 can be replaced by a simple, substituted aromatic ring suc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86c8a097e1c75222e7013c703f6e14c4
https://doi.org/10.1016/j.bmcl.2010.07.127
https://doi.org/10.1016/j.bmcl.2010.07.127
Autor:
F. Otu, Joseph A. Mancini, Dwight Macdonald, Rebecca Dias, Daniel Dube, L. Zhang, Patrick Lacombe, Pascal Jean Denis Goetghebeur, Angela Styhler, David Claveau, Suzanna Liu, Yves Girard, Zheng Huang, Mervyn J. Turner, Michel Gallant, William M. Abraham, K. Ng, Thomas R. Jones, F. Laliberte, Robert N. Young, Donald W. Nicholson
Publikováno v:
Biochemical Pharmacology. 73:1971-1981
Type 4 phosphodiesterases (PDE4) inhibitors are emerging therapeutics in the treatment of a number of chronic disorders including asthma, chronic obstructive pulmonary disease (COPD) and cognitive disorders. This study delineates the preclinical prof
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2765f56857f1438d13b1b2fb56afa4fc
https://doi.org/10.1016/j.bcp.2007.03.010
https://doi.org/10.1016/j.bcp.2007.03.010
Autor:
Mélissa Arbour, Gavin Chit Tsui, Jean-Pierre Falgueyret, Pierre-André Fournier, Yongxin Han, Michel Gallant, Patrick Lacombe, Daniel Dube, Daniel Simard, Elizabeth Cauchon, Austin Chen, Renee Aspiotis, Suzanna Liu, René St-Jacques, Christophe Mellon, Erich L. Grimm, Yeeman K. Ramtohul, Helene Juteau
Publikováno v:
Bioorganicmedicinal chemistry letters. 22(5)
The discovery and SAR of a series of potent renin inhibitors possessing a novel 3,4-diarylpiperidine scaffold are described herein. The resulting compound 38 exhibit low nanomolar plasma renin IC(50), had a clean CYP 3A4 profile and displayed micromo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72bbcef3547c253b1c7b45e16084feb3
https://pubmed.ncbi.nlm.nih.gov/22325946
https://pubmed.ncbi.nlm.nih.gov/22325946
Autor:
Laurence Dube, David Martin, Daniel Dube, Dan McKay, Michel Gallant, Robert Houle, Austin Chen, Dwight Macdonald, Bruce Mackay, Erich L. Grimm, Suzanna Liu, Sebastien Laliberte, Patrick Lacombe, Sébastien Gagné, David A. Powell, Mireille Gaudreault, Jean-François Lévesque
Publikováno v:
Bioorganicmedicinal chemistry letters. 20(17)
Time-dependent inhibitors of CYPs have the potential to perpetrate drug-drug interactions in the clinical setting. After finding that several leading compounds in a novel series of substituted amino propanamide renin inhibitors inactivated CYP3A4 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f193309cdedef2ef1eb3b94189c04f54
https://pubmed.ncbi.nlm.nih.gov/20673718
https://pubmed.ncbi.nlm.nih.gov/20673718
Autor:
Daigen Xu, George S. Robertson, Yanxia Zhu, Zheng Huang, D. MacDonald, M. Handa, C.S. Moore, F. Laliberte, Suzanna Liu, Y. Bureau
Publikováno v:
Neuropharmacology. 51(5)
A major obstacle in the therapeutic development of phosphodiesterase-4 (PDE4) inhibitors is the production of adverse side effects such as nausea and vomiting. Immunohistochemical detection of Fos-like immunoreactivity (FLI) was used to address the n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01768a70d8854330e867d103ec670d4e
https://pubmed.ncbi.nlm.nih.gov/16901513
https://pubmed.ncbi.nlm.nih.gov/16901513